Corvus Pharmaceu Financials
This page shows Corvus Pharmaceu (CRVS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Corvus Pharmaceu passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Corvus Pharmaceu generates $0.41 in operating cash flow (-$25.4M OCF vs -$62.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Corvus Pharmaceu's EBITDA was -$27.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 18.1% from the prior year.
Corvus Pharmaceu reported -$62.3M in net income in fiscal year 2024. This represents a decrease of 130.5% from the prior year.
Corvus Pharmaceu earned $-1.02 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 82.1% from the prior year.
Corvus Pharmaceu held $8.7M in cash against $0 in long-term debt as of fiscal year 2024.
Corvus Pharmaceu had 68M shares outstanding in fiscal year 2024. This represents an increase of 38.5% from the prior year.
Corvus Pharmaceu invested $19.4M in research and development in fiscal year 2024. This represents an increase of 17.3% from the prior year.
CRVS Income Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $8.5M+61.9% | $5.2M | N/A | $4.0M | N/A | $10.4M | N/A | $7.0M |
| SG&A Expenses | $2.1M+4.2% | $2.0M | N/A | $1.6M | N/A | $2.1M | N/A | $2.1M |
| Operating Income | -$10.6M-45.7% | -$7.3M | N/A | -$5.6M | N/A | -$12.5M | N/A | -$9.0M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | $0 | N/A | $0 | N/A | $0 | N/A | $0 |
| Net Income | -$10.2M+74.7% | -$40.2M | N/A | -$6.0M | N/A | -$14.8M | N/A | -$10.7M |
| EPS (Diluted) | $-0.12+80.0% | $-0.60 | N/A | $-0.12 | N/A | $-0.32-60.0% | $-0.20+16.7% | $-0.24 |
CRVS Balance Sheet
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $80.5M+16.8% | $68.9M+51.3% | $45.6M-12.3% | $51.9M-23.9% | $68.2M-15.1% | $80.3M-26.6% | $109.5M-8.3% | $119.3M |
| Current Assets | $66.9M+23.0% | $54.4M+94.6% | $28.0M-15.5% | $33.1M-24.2% | $43.7M-14.8% | $51.3M-28.1% | $71.3M-9.5% | $78.8M |
| Cash & Equivalents | $2.9M-67.2% | $8.7M-30.7% | $12.6M-37.2% | $20.1M+52.8% | $13.2M-46.5% | $24.6M-61.3% | $63.5M-12.2% | $72.3M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $32K-57.3% | $75K+188.5% | $26K+136.4% | $11K-98.1% | $588K | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $8.7M-76.0% | $36.3M+429.0% | $6.9M-10.2% | $7.7M-36.9% | $12.1M-22.6% | $15.7M+27.4% | $12.3M-13.3% | $14.2M |
| Current Liabilities | $8.1M-77.2% | $35.4M+415.4% | $6.9M-5.9% | $7.3M-32.1% | $10.8M-23.1% | $14.0M+44.2% | $9.7M-14.3% | $11.3M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $71.8M+120.4% | $32.6M-15.8% | $38.7M-12.7% | $44.3M-21.1% | $56.1M-13.2% | $64.7M-33.4% | $97.2M-7.6% | $105.1M |
| Retained Earnings | -$400.0M-0.7% | -$397.0M-18.6% | -$334.7M-2.0% | -$328.1M-6.6% | -$307.7M-3.3% | -$297.9M-11.8% | -$266.4M-3.6% | -$257.1M |
CRVS Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$9.6M-13.0% | -$8.5M-63.8% | -$5.2M+4.9% | -$5.4M+28.0% | -$7.5M-8.9% | -$6.9M-1.1% | -$6.9M+18.6% | -$8.4M |
| Capital Expenditures | $0 | N/A | $0 | $0 | $0-100.0% | $265K | N/A | N/A |
| Free Cash Flow | -$9.6M | N/A | -$5.2M+4.9% | -$5.4M+28.0% | -$7.5M-4.9% | -$7.2M | N/A | N/A |
| Investing Cash Flow | -$2.6M+57.0% | -$6.1M-162.4% | -$2.3M-113.2% | $17.5M+552.0% | -$3.9M-227.7% | $3.0M+252.1% | -$2.0M-157.6% | $3.5M |
| Financing Cash Flow | $360K-98.1% | $18.6M | $0-100.0% | $335K | N/A | N/A | $18K-99.9% | $18.3M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CRVS Financial Ratios
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | 30.8% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -12.6%+55.8pp | -68.4% | N/A | -11.6% | N/A | -18.5% | N/A | -8.9% |
| Current Ratio | 8.29+6.8 | 1.54-2.5 | 4.07-0.5 | 4.53+0.5 | 4.06+0.4 | 3.67-3.7 | 7.36+0.4 | 6.97 |
| Debt-to-Equity | 0.12-1.0 | 1.12+0.9 | 0.180.0 | 0.17-0.0 | 0.22-0.0 | 0.24+0.1 | 0.130.0 | 0.13 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Corvus Pharmaceu profitable?
No, Corvus Pharmaceu (CRVS) reported a net income of -$62.3M in fiscal year 2024.
What is Corvus Pharmaceu's earnings per share (EPS)?
Corvus Pharmaceu (CRVS) reported diluted earnings per share of $-1.02 for fiscal year 2024. This represents a -82.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Corvus Pharmaceu's EBITDA?
Corvus Pharmaceu (CRVS) had EBITDA of -$27.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Corvus Pharmaceu's operating cash flow?
Corvus Pharmaceu (CRVS) generated -$25.4M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Corvus Pharmaceu's total assets?
Corvus Pharmaceu (CRVS) had $68.9M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Corvus Pharmaceu spend on research and development?
Corvus Pharmaceu (CRVS) invested $19.4M in research and development during fiscal year 2024.
How many shares does Corvus Pharmaceu have outstanding?
Corvus Pharmaceu (CRVS) had 68M shares outstanding as of fiscal year 2024.
What is Corvus Pharmaceu's current ratio?
Corvus Pharmaceu (CRVS) had a current ratio of 1.54 as of fiscal year 2024, which is generally considered healthy.
What is Corvus Pharmaceu's debt-to-equity ratio?
Corvus Pharmaceu (CRVS) had a debt-to-equity ratio of 1.12 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Corvus Pharmaceu's return on assets (ROA)?
Corvus Pharmaceu (CRVS) had a return on assets of -90.4% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Corvus Pharmaceu's cash runway?
Based on fiscal year 2024 data, Corvus Pharmaceu (CRVS) had $8.7M in cash against an annual operating cash burn of $25.4M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Corvus Pharmaceu's Piotroski F-Score?
Corvus Pharmaceu (CRVS) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Corvus Pharmaceu's earnings high quality?
Corvus Pharmaceu (CRVS) has an earnings quality ratio of 0.41x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.